You are here

Share:

Search Technologies

Showing 1-20 of 71 results found

Biological Semiconductors

The National Cancer Institute's Cancer Diagnostic Program and the Food and Drug Administration's Center for Devices and Radiological Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biological semiconductors as diagnostic sensors.

Screening of Menkes Disease in Newborns that are likely to Benefit from Copper Treatment

The Eunice Kennedy Shriver National Institute of Child Health and Human Development's (NICHD) Molecular Medicine Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, or evaluate on a large-scale, population-based newborn screening for Menkes disease (also known as kinky hair disease).

Assay for Arf GTP-binding Proteins

The National Cancer Institute's Laboratory of Cellular and Molecular Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize an antibody-based proteomics assay.

Co-Transcriptional Assembly of Modified RNA Nanoparticles

The National Cancer Institute’s Nanobiology Program seeks parties interested in collaborative research to co-develop a method to generate RNA molecules suitable for nanoparticle and biomedical applications.

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.

Anti-Tumor Agents That Effect Premature Chromosome Condensation

The National Cancer Institute Laboratory of Molecular Pharmacology seeks parties interested in licensing or collaborative research to co-evelop, evaluate, or commercialize lasonolide compounds as novel anti-cancer agents.

Collaboration Opportunities with the Cancer Human Biobank (caHUB) at NCI

The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute has developed the Cancer Human Biobank (caHUB), which is a unique infrastructure for collecting biospecimens for the purpose of conducting biospecimen research. Biospecimens from the BPV program will be made available to collaborators with the capability to perform molecular analysis as part of a collaborative research agreement with the NCI-BBRB.

Method and device for selectively labeling RNA

The National Cancer Institute's Structure Biophysics Lab seeks partners interested in licensing or co-developing a technology to site-specifically label RNA.

A Secure, Web-Based Biorepository Database

The National Cancer Institute seeks collaborators to co-develop a secure, web-based system that manages multi-dimensional data models on biospecimens.

Automated Cancer Detection (CAD) Using MRI

The inventions listed are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Biomarker signature development: microRNAs for biodosimetry

Alterations in microRNAs (miRNAs), a type of small non-coding RNAs, have been reported in cells/tumors subjected to radiation exposure, implying that miRNAs play an important role in cellular stress response to radiation. NCI researchers evaluated small non-coding RNAs, long non-coding RNAs (lncRNA), and mRNA, as potential non-invasive biomarkers for radiation biodosimetry. The NCI Radiation Oncology Branch seeks parties interested in licensing or co-development of RNA biomarker signature(s) for radiation biodosimetry.

High-throughput Assay to Identify New Cancer Drugs

The National Cancer Institute, Laboratory of Molecular Pharmacology seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.

Pages